1. Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?
- Author
-
Arnaud Riat, Emmanouil Glampedakis, Yves Chalandon, Federica Giannotti, Romain Samuel Roth, Christian van Delden, Dionysios Neofytos, Stavroula Masouridi-Levrat, Adrien Nicolas Fischer, Laurent Kaiser, Antoine Poncet, and Anne-Claire Mamez
- Subjects
ddc:616 ,Allogeneic hematopoietic cell transplant recipients ,invasive aspergillosis ,ddc:618 ,Hematopoietic cell ,Epidemiology ,business.industry ,Invasive mold infections ,mortality ,Major Articles ,invasive mold infections ,Infectious Diseases ,AcademicSubjects/MED00290 ,Oncology ,Immunology ,Invasive aspergillosis ,Medicine ,epidemiology ,Mortality ,business ,allogeneic hematopoietic cell transplant recipients ,ddc:613 - Abstract
Background Despite progress in diagnostic, prevention, and treatment strategies, invasive mold infections (IMIs) remain the leading cause of mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients. Methods We describe the incidence, risk factors, and mortality of allo-HCT recipients with proven/probable IMI in a retrospective single-center 10-year (01/01/2010–01/01/2020) cohort study. Results Among 515 allo-HCT recipients, 48 (9.3%) patients developed 51 proven/probable IMI: invasive aspergillosis (IA; 34/51, 67%), mucormycosis (9/51, 18%), and other molds (8/51, 15%). Overall, 35/51 (68.6%) breakthrough IMIs (bIMIs) were identified: 22/35 (62.8%) IA and 13/35 (37.1%) non-IA IMI. One-year IMI cumulative incidence was 7%: 4.9% and 2.1% for IA and non-IA IMI, respectively. Fourteen (29.2 %), 10 (20.8%), and 24 (50.0%) patients were diagnosed during the first 30, 31–180, and >180 days post-HCT, respectively. Risk factors for IMI included prior allo-HCT (sub hazard ratio [SHR], 4.06; P = .004) and grade ≥2 acute graft-vs-host disease (aGvHD; SHR, 3.52; P Conclusions IA mortality has remained relatively unchanged during the last 2 decades. More than two-thirds of allo-HCT recipients with IMI die by 1 year post–IMI diagnosis. Dedicated intensified research efforts are required to further improve clinical outcomes.
- Published
- 2021